Cargando…
Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
PURPOSE: TrasGEX is a second-generation monoclonal antibody of trastuzumab, glyco-optimised to enhance antibody-dependent cellular cytotoxicity while fully retaining trastuzumab’s antigen-binding properties to human epidermal growth factor receptor 2 (HER2). A phase I dose-escalation study was condu...
Autores principales: | Fiedler, Walter, Stoeger, Herbert, Perotti, Antonella, Gastl, Guenther, Weidmann, Jens, Dietrich, Bruno, Baumeister, Hans, Danielczyk, Antje, Goletz, Steffen, Salzberg, Marc, De Dosso, Sara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045773/ https://www.ncbi.nlm.nih.gov/pubmed/30018811 http://dx.doi.org/10.1136/esmoopen-2018-000381 |
Ejemplares similares
-
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
por: Eisner, Florian, et al.
Publicado: (2015) -
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
por: Fiedler, Walter, et al.
Publicado: (2018) -
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts
por: Goletz, Christoph, et al.
Publicado: (2018) -
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy
por: Hart, Felix, et al.
Publicado: (2017) -
Gex, Mardi
Publicado: (2004)